• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过共晶化增强那格列奈的药物行为:共晶形成的物理化学评估和差示扫描量热法在其定量表征中的明智应用。

Enhancing the Pharmaceutical Behavior of Nateglinide by Cocrystallization: Physicochemical Assessment of Cocrystal Formation and Informed Use of Differential Scanning Calorimetry for Its Quantitative Characterization.

机构信息

Department of Chemistry, C.S.G.I, Physical-Chemistry Section, University of Pavia, Via Taramelli 16, 27100 Pavia, Italy.

Department of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.

出版信息

J Pharm Sci. 2019 Apr;108(4):1529-1539. doi: 10.1016/j.xphs.2018.11.033. Epub 2018 Nov 23.

DOI:10.1016/j.xphs.2018.11.033
PMID:30476510
Abstract

The aim of this study was to synthetize cocrystals of nateglinide, an antidiabetic agent of biopharmaceutics classification system Class IIa, as a strategy to improve both the solubility and the dissolution rate of the drug. Benzamide was selected by a screening procedure as a suitable coformer, and binary mixtures with different compositions were prepared and analyzed by differential scanning calorimetry (DSC). An in-depth analysis of DSC data allowed obtaining both the eutectic mixture and cocrystal compositions. The rationale of such an analysis was highlighted and explained. Cocrystals were prepared by kneading and solvent evaporation. Their formation was proved by DSC and confirmed by X-ray powder diffraction, solid-state nuclear magnetic resonance, and Fourier-transform infrared spectroscopy. The functional groups involved in the interaction leading to cocrystals formation were investigated by spectroscopic techniques. The in vitro dissolution profiles show that cocrystals have definite better pharmaceutical performances than the pure drug.

摘要

本研究旨在合成那格列奈的共晶,那格列奈是生物药剂学分类系统 IIa 类的抗糖尿病药物,作为提高药物溶解度和溶解速率的策略。通过筛选程序,苯甲酰胺被选为合适的共晶形成剂,并制备了不同组成的二元混合物,并通过差示扫描量热法(DSC)进行分析。对 DSC 数据的深入分析可以获得共晶混合物和共晶的组成。强调并解释了这种分析的原理。通过 kneading 和溶剂蒸发制备共晶。通过 DSC 证明了它们的形成,并通过 X 射线粉末衍射、固态核磁共振和傅里叶变换红外光谱得到了确认。通过光谱技术研究了导致共晶形成的相互作用涉及的官能团。体外溶解曲线表明,共晶具有比纯药物更好的药物性能。

相似文献

1
Enhancing the Pharmaceutical Behavior of Nateglinide by Cocrystallization: Physicochemical Assessment of Cocrystal Formation and Informed Use of Differential Scanning Calorimetry for Its Quantitative Characterization.通过共晶化增强那格列奈的药物行为:共晶形成的物理化学评估和差示扫描量热法在其定量表征中的明智应用。
J Pharm Sci. 2019 Apr;108(4):1529-1539. doi: 10.1016/j.xphs.2018.11.033. Epub 2018 Nov 23.
2
Structural Characterization and Pharmaceutical Properties of Three Novel Cocrystals of Ethenzamide With Aliphatic Dicarboxylic Acids.埃替唑胺三种新型无定型物与脂肪族二元羧酸共晶的结构特征和药物性能。
J Pharm Sci. 2019 Apr;108(4):1476-1485. doi: 10.1016/j.xphs.2018.10.060. Epub 2018 Nov 8.
3
Synthesis of a Glibenclamide Cocrystal: Full Spectroscopic and Thermal Characterization.格列本脲共晶的合成:全光谱和热特性分析。
J Pharm Sci. 2018 Jun;107(6):1597-1604. doi: 10.1016/j.xphs.2018.01.029. Epub 2018 Feb 9.
4
Improving the solubility of dexlansoprazole by cocrystallization with isonicotinamide.通过与异烟酰胺共结晶提高右兰索拉唑的溶解度。
Eur J Pharm Sci. 2016 Mar 31;85:47-52. doi: 10.1016/j.ejps.2016.01.029. Epub 2016 Feb 1.
5
Matrix-assisted cocrystallization (MAC) simultaneous production and formulation of pharmaceutical cocrystals by hot-melt extrusion.基质辅助共结晶(MAC):通过热熔挤出同时制备药物共晶体并进行制剂。
J Pharm Sci. 2014 Sep;103(9):2904-2910. doi: 10.1002/jps.23983. Epub 2014 May 7.
6
A novel strategy for pharmaceutical cocrystal generation without knowledge of stoichiometric ratio: myricetin cocrystals and a ternary phase diagram.一种无需知晓化学计量比即可生成药物共晶体的新策略:杨梅素共晶体及三元相图
Pharm Res. 2015 Jan;32(1):47-60. doi: 10.1007/s11095-014-1443-y. Epub 2014 Jun 18.
7
Cocrystal Construction Between Rosuvastatin Calcium and L-asparagine with Enhanced Solubility and Dissolution Rate.瑞舒伐他汀钙与L-天冬酰胺的共晶构建及其溶解度和溶出速率的提高
Turk J Pharm Sci. 2021 Dec 31;18(6):790-798. doi: 10.4274/tjps.galenos.2021.62333.
8
Novel Aceclofenac Cocrystals with l-Cystine: Virtual Coformer Screening, Mechanochemical Synthesis, and Physicochemical Investigations.新型 Aceclofenac 与 l-胱氨酸共晶:虚拟共晶筛选、机械化学合成及理化性质研究。
Curr Drug Deliv. 2021;18(1):88-100. doi: 10.2174/1567201817666200817110949.
9
Improved pharmaceutical properties of ritonavir through co-crystallization approach with liquid-assisted grinding method.通过液辅助研磨法与利托那韦共结晶方法改善利托那韦的药物性质。
Drug Dev Ind Pharm. 2021 Oct;47(10):1633-1642. doi: 10.1080/03639045.2022.2042553. Epub 2022 Feb 25.
10
Characterization and therapeutic efficacy evaluation of glimepiride and L-arginine co-amorphous formulation prepared by supercritical antisolvent process: Influence of molar ratio and preparation methods.超临界抗溶剂法制备格列美脲与 L-精氨酸共无定形物的特性及疗效评价:摩尔比和制备方法的影响。
Int J Pharm. 2020 May 15;581:119232. doi: 10.1016/j.ijpharm.2020.119232. Epub 2020 Mar 30.

引用本文的文献

1
Pimozide and Adipic Acid: A New Multicomponent Crystalline Entity for Improved Pharmaceutical Behavior.匹莫齐特与己二酸:一种改善药物性能的新型多组分晶体实体。
Molecules. 2024 Nov 27;29(23):5610. doi: 10.3390/molecules29235610.
2
A review on advancement of cocrystallization approach and a brief on screening, formulation and characterization of the same.共结晶方法的进展综述及其筛选、制剂和表征简述。
Heliyon. 2024 Apr 1;10(7):e29057. doi: 10.1016/j.heliyon.2024.e29057. eCollection 2024 Apr 15.
3
Synthesis and Characterization of Carvedilol-Etched Halloysite Nanotubes Composites with Enhanced Drug Solubility and Dissolution Rate.
载有卡维地洛的刻蚀埃洛石纳米管复合材料的合成与表征,其药物溶解度和溶出速率得到增强。
Molecules. 2023 Apr 12;28(8):3405. doi: 10.3390/molecules28083405.
4
Tablet Formulations of Polymeric Electrospun Fibers for the Controlled Release of Drugs with pH-Dependent Solubility.用于控释具有pH依赖性溶解度药物的聚合物电纺纤维片剂配方。
Polymers (Basel). 2022 May 23;14(10):2127. doi: 10.3390/polym14102127.
5
Continuous Manufacture and Scale-Up of Theophylline-Nicotinamide Cocrystals.茶碱-烟酰胺共晶体的连续制造与放大生产
Pharmaceutics. 2021 Mar 20;13(3):419. doi: 10.3390/pharmaceutics13030419.